Zusammenfassung
Zielgerichtete Therapien sowie die Immuntherapie haben die therapeutische Landschaft des metastasierten Nierenzellkarzinoms bzw. des metastasierten Urothelkarzinoms in den letzten Jahren revolutioniert und werden heute dort breit angewendet. Beim Prostatakarzinom werden zielgerichtete Therapien nur begrenzt eingesetzt und sind, mit Ausnahme des PARP-Inhibitors Olaparib, aktuell kein Therapiestandard. Eine Vielzahl von möglichen Kombinationen wird im Moment in klinischen Studien untersucht. Der PARP-Inhibitor Olaparib kann beim mCRPC nach Progress unter NHA („next generation hormonal agents“) und bei Nachweis einer deletären BRCA1- bzw. BRCA2-Mutation eingesetzt werden bzw. in Kombination mit Abirateron bei Patienten im mCRPC, bei denen eine Chemotherapie klinisch nicht indiziert ist. Dieses Kapitel soll neben der aktuellen Studienlandschaft mit möglichen positiven Signalen spezifische Patientenkollektive vorstellen, bei denen ein Einsatz dieser Therapien möglicherweise sinnvoll sein könnte.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Literatur
Agarwal N et al (2022) Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). Lancet Oncol 23(7):899–909
Agarwal, N et al (2023) Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet 402(10398): 291–303
Antonarakis ES et al (2020) Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 Study. J Clin Oncol 38(5):395–405
Chi KN et al (2022) Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. J Clin Oncol 40(6_suppl):12–12
Choudhury AD (2022) PTEN-PI3K pathway alterations in advanced prostate cancer and clinical implications. Prostate 82(Suppl 1):S60–S72
del Rivero J, Kohn EC (2017) PARP Inhibitors: the cornerstone of DNA repair-targeted therapies. Oncology (Williston Park) 31(4):265–273
Deluce JE et al (2022) Emerging biomarker-guided therapies in prostate cancer. Curr Oncol 29(7):5054–5076
Guney Eskiler G et al (2022) Mechanisms of abemaciclib, a CDK4/6 inhibitor, induced apoptotic cell death in prostate cancer cells in vitro. Transl Oncol 15(1):101243
Hoefflin R et al (2021) Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis. Cancers (Basel) 13, 10.3390/cancers13051151
Hussain M et al (2020) Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med 383(24):2345–2357
Merck (2022a) Merck announces KEYLYNK-010 trial evaluating KEYTRUDA® (pembrolizumab) in combination with lynparza® (olaparib) in patients with metastatic castration-resistant prostate cancer to stop for futility. https://www.merck.com/news/merck-announces-keylynk-010-trial-evaluating-keytruda-pembrolizumab-in-combination-with-lynparza-olaparib-in-patients-with-metastatic-castration-resistant-prostate-cancer-to-stop-for-f/, Download 29.08.2022
Merck (2022b) Merck provides update on phase 3 KEYNOTE-921 trial evaluating Keytruda® (pembrolizumab) plus chemotherapy in patients with metastatic castration-resistant prostate cancer. https://www.merck.com/news/merck-provides-update-on-phase-3-keynote-921-trial-evaluating-keytruda-pembrolizumab-plus-chemotherapy-in-patients-with-metastatic-castration-resistant-prostate-cancer/. Download 29.08.2022
Merseburger AS et al (2021) Genomic testing in patients with metastatic castration-resistant prostate cancer: a pragmatic guide for clinicians. Eur Urol 79(4):519–529
Netto GJ et al (2022) The 2022 World Health Organization classification of tumors of the urinary system and male genital organs – part B: Prostate and urinary tract tumors. Eur Urol 82(5):469–482
Petrylak DP et al (2021) 579MO CheckMate 9KD cohort A2 final analysis: Nivolumab (NIVO) + rucaparib for chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC). Ann Oncol 32:S629–S630
Saad F et al (2022) PROpel: phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 40(6_suppl):11–11
Saad F et al (2023) Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol
Smith MR et al (2022) CYCLONE 2: A phase 2/3, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 40(6_suppl):TPS198–TPS198
Sundararajan S, Ahmed A, Goodman OB (2011) The relevance of BRCA genetics to prostate cancer pathogenesis and treatment. Clin Adv Hematol Oncol 9(10):748–755
Sweeney C et al (2021) Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet 398(10295):131–142
Templeton AJ et al (2013) Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). Eur Urol 64(1):150–158
Yu E et al (2021) 73P Association between homologous recombination repair mutations and response to pembrolizumab (pembro) plus olaparib (ola) in metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A biomarker analysis. Ann Oncol 32:S387
Yu EY et al (2022) Pembrolizumab plus docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b/2 KEYNOTE-365 Cohort B Study. Eur Urol 82(1):22–30
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 Der/die Autor(en), exklusiv lizenziert an Springer-Verlag GmbH, DE, ein Teil von Springer Nature
About this chapter
Cite this chapter
Grabbert, M., Sigle, A., Michaelis, J., Gratzke, C. (2023). Targeted Therapien und Immuntherapie. In: Merseburger, A.S., Roesch, M.C. (eds) Metastasiertes Prostatakarzinom. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-67297-6_10
Download citation
DOI: https://doi.org/10.1007/978-3-662-67297-6_10
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-67296-9
Online ISBN: 978-3-662-67297-6
eBook Packages: Medicine (German Language)